Acorah Software Products - Accounts Production16.5.460falsetruefalsetrueNo description of principal activity1 August 202431 July 202531 July 202515869357Ms Nora Quainooiso4217:GBPiso4217:EURiso4217:USDxbrli:sharesxbrli:purexbrli:pure158693572024-07-31158693572025-07-31158693572024-08-012025-07-3115869357frs-core:CurrentFinancialInstruments2025-07-3115869357frs-bus:PrivateLimitedCompanyLtd2024-08-012025-07-3115869357frs-bus:FilletedAccounts2024-08-012025-07-3115869357frs-bus:Micro-entities2024-08-012025-07-3115869357frs-bus:AuditExempt-NoAccountantsReport2024-08-012025-07-3115869357frs-bus:Director12024-08-012025-07-31
Registered number: 15869357
Naqpharma Ltd
Unaudited Financial Statements
For The Year Ended 31 July 2025
Naqpharma Ltd
Balance Sheet
As At 31 July 2025
Balance Sheet
Registered number: 15869357
2025
£
Current assets
7,097
Creditors: Amounts Falling Due Within One Year
(6,092)
NET CURRENT ASSETS
1,005
TOTAL ASSETS LESS CURRENT LIABILITIES
1,005
NET ASSETS
1,005
CAPITAL AND RESERVES
1,005
Notes
1.General Information
Naqpharma Ltd is a private company, limited by shares, incorporated in England & Wales, registered number 15869357. The registered office is 72 KYNASTON ROAD, THORNTON HEATH, LONDON, CR7 7AY.
2.Average Number of Employees
Average number of employees, including directors, during the year was: 1
1
For the year ending 31 July 2025 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.
The member has not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.
The director acknowledges her responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.
These accounts have been prepared in accordance with the micro-entity provisions and delivered in accordance with the provisions applicable to companies subject to the small companies regime.